Lung cancer trials in China

In China 1143 Also abroad 2747

1,143 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Phase II Study of SKB571 in Patients With Lung Cancer
Where
Guangzhou, Zhengzhou
Age
18 years to 75 years
People
295
Run by
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
See details and how to joinNCT07230405
Phase 1Taking people
IMP3-saRNA Vaccine in Advanced NSCLC
Where
Chengdu
Age
18 years and over
People
9
Run by
West China Hospital
See details and how to joinNCT07561723
Phase 1/2Taking people
Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II
Where
Chengdu
Age
18 years to 80 years
People
40
Run by
Sichuan University
See details and how to joinNCT06195189
Phase 1Taking people
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
Where
Chengdu
Age
18 years to 75 years
People
10
Run by
Sichuan University
See details and how to joinNCT06431685
Phase 2Taking people
A Study of SKB518 in Patients With Lung Cancer
Where
Beijing, Changsha, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenzhen, Taiyuan, Taizhou, Tianjin, Ürümqi, Wuhan, Xiangyang, Zhengzhou
Age
18 years to 75 years
People
192
Run by
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
See details and how to joinNCT07019675
Phase 2Taking people
SKB500 Combinations in Patients With Small Cell Lung Cancer
Where
Guangzhou
Age
18 years to 75 years
People
80
Run by
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
See details and how to joinNCT07296809
Phase 1/2Taking people
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Where
Chengdu
Age
18 years to 75 years
People
45
Run by
Sichuan University
See details and how to joinNCT06217757
Phase 2Taking people
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
Where
Nanchang
Age
18 years to 75 years
People
156
Run by
Second Affiliated Hospital of Nanchang University
See details and how to joinNCT06554613
Phase 2Not yet taking people in China
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
Where
Chengdu
Age
18 years to 75 years
People
30
Run by
Sichuan University
See details and how to joinNCT07258147
No phaseTaking people
Septum-guided Segmentectomy for Deep Early-stage Lung Cancer (SGS2512)
Where
Shanghai
Age
18 years to 80 years
People
89
Run by
Shanghai Chest Hospital
See details and how to joinNCT07564557
No phaseTaking people
Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment
Where
Shanghai
Age
18 years and over
People
500
Run by
Shanghai Chest Hospital
See details and how to joinNCT07565532
Phase 3Taking people
A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
Where
Beijing, Guangzhou
Age
18 years and over
People
300
Run by
Beijing Pearl Biotechnology Limited Liability Company
See details and how to joinNCT06930794
Phase 1Taking people
This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
Where
Beijing
Age
18 years to 75 years
People
55
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07249879
Phase 3Not yet taking people in China
Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer
Where
Beijing
Age
18 years to 75 years
People
204
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07560358
No phaseTaking people
Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device
Where
Tianjin
Age
18 years and over
People
50
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07561567
Phase 2Not yet taking people in China
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
Where
Chengdu
Age
18 years to 80 years
People
39
Run by
Sichuan Cancer Hospital and Research Institute
See details and how to joinNCT07561983
No phaseTaking people
Shared Decision Making in Patients With Lung Cancer
Where
Chengdu
Age
18 years and over
People
190
Run by
Sichuan Cancer Hospital and Research Institute
See details and how to joinNCT05191485
No phaseTaking people
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Where
Beijing, Hohhot, Zhengzhou
Age
18 years and over
People
2,400
Run by
Beijing Chao Yang Hospital
See details and how to joinNCT06950697
Phase 2Taking people
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
Where
Guangzhou
Age
18 years to 75 years
People
28
Run by
Yang Hong
See details and how to joinNCT07309952
Phase 1Not yet taking people in China
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
Where
Shanghai
Age
18 years and over
People
138
Run by
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT07558200
Phase 1/2Taking people
Exploration of the Application of Methotrexate-loaded Drug Vesicles in Intrathecal Injection for Meningeal Metastasis of Lung Cancer
Where
Zhengzhou
Age
18 years and over
People
14
Run by
Henan Cancer Hospital
See details and how to joinNCT07559097
Phase 2Taking people
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
Where
Beijing, Cangzhou, Tianjin
Age
18 years and over
People
30
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07058948
Phase 2Not yet taking people in China
Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
Where
Tianjin
Age
18 years and over
People
28
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07379398
Phase 1Taking people
Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
Where
Shanghai
Age
18 years to 75 years
People
100
Run by
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
See details and how to joinNCT07231445
Phase 2Not yet taking people in China
GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer
Where
Guangzhou
Age
18 years to 75 years
People
90
Run by
Genfleet Therapeutics (Shanghai) Inc.
See details and how to joinNCT07554859